Iressa与全脑放疗同期治疗非小细胞肺癌多发脑转移临床应用效果分析

Effect of Lressa Combined with Whole-brain Radiotherapy on Multiple Brain Metastases of Non-small Cell Lung Cancer

目的综合分析Iressa(吉非替尼)与全脑放疗同期治疗非小细胞肺癌脑多发转移临床应用效果。方法选取56例非小细胞肺癌脑转移患者作为研究对象,按照入院顺序随机分为观察组和对照组,每组均为28例。观察组应用全脑放疗同时口服吉非替尼的治疗方法,对照组应用全脑放疗后口服吉非替尼的治疗方法。结果 (1)观察组的部分缓解率、疾病控制率、治疗有效率显著高于对照组(P<0.05),观察组患者的病情进展率显著低于对照组(P<0.05);(2)治疗前,两组患者的癌胚抗原、表皮生长因子受体含量以及血清中非小细胞肺癌抗原水平比较无统计学意义(P>0.05);治疗后,观察组表皮生长因子受体含量以及血清中非小细胞肺癌抗原水平显著低于对照组(P<0.05);(3)观察组不良反应发生率(呕吐、恶心和疲乏等)显著低于对照组(P<0.05),两组患者在腹泻和骨髓抑制等不良反应发生率比较无统计学意义(P>0.05)。结论全脑放疗同时口服吉非替尼的临床研究价值显著高于全脑放疗后口服吉非替尼的价值。

Objective To analyze the clinical effect of Iressa （gefitinib） and whole brain radiotherapy in the treatment of non-small cell lung cancer with multiple metastases. Methods 56 cases of non-small cell lung cancer patients with brain me- tastases were randomly divided into the observation group and the control group according to admission order. 28 cases. The treat- ment group was treated with whole brain radiotherapy and gefitinib. The control group was treated with gefitinib after whole brain radiotherapy. SPSS20.0 statistical software for statistical analysis of the 2 groups of patients after receiving the relevant part of the remission rate, disease progression rate, disease control rate,treatment efficiency, carcinoembryonic antigen, epidermal growth fac- tor receptor, adverse reaction rates As well as serum non-small cell lung cancer antigen and other parameters. Results The rate of partial remission, disease control and effective rate of the observation group were significantly higher than those of the control group （P 〈 0.05）, and the progression rate of the observation group was significantly lower than that of the control group （ P 〈 0.05）. There was no significant difference in the levels of CEA, EGFR and serum NSCLC antigen between the two groups （ P 〉 0. 05 ）. After treatment, the levels of epidermal growth factor receptor （EGFR） and serum non-small cell （ P 〈 0.05 ） ; The inci- dence of adverse reactions （vomiting, nausea and fatigue） in the experimental group was significantly lower than that of the con- trol group （P 〈 0.05）. The incidence of diarrhea and myelosuppression in the two groups was significantly lower than that in the control group The incidence of adverse reactions was not statistically significant （P 〉 0. 05）. Conclusion The value of gefitinib in the whole brain radiotherapy combined with gefitinib is significantly higher than that in the whole brain after radiotherapy.